ARTICLE | Product Development
Payload Payoff
ImmunGene, Cephalon Australia to deliver interferon to tumors
February 7, 2011 8:00 AM UTC
The apoptotic effects of interferon alpha are well established and marketed versions of the cytokine are used to treat a variety of hematological malignancies. But side effects have limited its use. Now ImmunGene Inc. has its first deal for a technology to selectively deliver IFN alpha to treat blood cancers and solid tumors.
Cephalon Australia Pty. Ltd., a subsidiary of Cephalon Inc. will have a four-year option to license ImmunGene's IFN payload technology for up to six undisclosed cancer targets from Cephalon...